239 related articles for article (PubMed ID: 15979321)
1. Management of patients with higher risk myelodysplastic syndromes.
Fukumoto JS; Greenberg PL
Crit Rev Oncol Hematol; 2005 Nov; 56(2):179-92. PubMed ID: 15979321
[TBL] [Abstract][Full Text] [Related]
2. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome.
Beran M
Int J Hematol; 2000 Aug; 72(2):139-50. PubMed ID: 11039661
[TBL] [Abstract][Full Text] [Related]
3. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.
Vey N; Bosly A; Guerci A; Feremans W; Dombret H; Dreyfus F; Bowen D; Burnett A; Dennis M; Ribrag V; Casadevall N; Legros L; Fenaux P
J Clin Oncol; 2006 Jun; 24(16):2465-71. PubMed ID: 16651646
[TBL] [Abstract][Full Text] [Related]
4. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.
Schiller GJ; Slack J; Hainsworth JD; Mason J; Saleh M; Rizzieri D; Douer D; List AF
J Clin Oncol; 2006 Jun; 24(16):2456-64. PubMed ID: 16651647
[TBL] [Abstract][Full Text] [Related]
5. New agents in myelodysplastic syndromes.
Jabbour EJ; Giles FJ
Curr Hematol Rep; 2005 May; 4(3):191-9. PubMed ID: 15865871
[TBL] [Abstract][Full Text] [Related]
6. Hemopoietic cell transplantation for the myelodysplastic syndromes.
Scott BL; Deeg HJ
Arch Immunol Ther Exp (Warsz); 2005; 53(4):297-307. PubMed ID: 16088314
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
8. Autologous stem cell transplantation in myelodysplastic syndromes.
de Witte T; Suciu S; Brand R; Muus P; Kröger N
Semin Hematol; 2007 Oct; 44(4):274-7. PubMed ID: 17961727
[TBL] [Abstract][Full Text] [Related]
9. Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?
Steensma DP
Best Pract Res Clin Haematol; 2012 Dec; 25(4):443-51. PubMed ID: 23200541
[TBL] [Abstract][Full Text] [Related]
10. Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes.
Fenaux P; Ades L
Leuk Res; 2009 Dec; 33 Suppl 2():S7-11. PubMed ID: 20004796
[TBL] [Abstract][Full Text] [Related]
11. Progress in intensive chemotherapy for high-risk myelodysplastic syndromes.
Sanz GF; Sanz MA
Forum (Genova); 1999; 9(1):63-71. PubMed ID: 10101211
[TBL] [Abstract][Full Text] [Related]
12. An update on the treatment of myelodysplastic syndromes.
Kurtin SE; Demakos EP
Clin J Oncol Nurs; 2010 Jun; 14(3):E29-44. PubMed ID: 20529786
[TBL] [Abstract][Full Text] [Related]
13. The evolution of hematopoietic SCT in myelodysplastic syndrome.
Kindwall-Keller T; Isola LM
Bone Marrow Transplant; 2009 Apr; 43(8):597-609. PubMed ID: 19252532
[TBL] [Abstract][Full Text] [Related]
14. Novel agents for the management of myelodysplastic syndromes.
Meletis J; Viniou N; Terpos E
Med Sci Monit; 2006 Sep; 12(9):RA194-206. PubMed ID: 16940944
[TBL] [Abstract][Full Text] [Related]
15. IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.
Nevill TJ; Shepherd JD; Sutherland HJ; Abou Mourad YR; Lavoie JC; Barnett MJ; Nantel SH; Toze CL; Hogge DE; Forrest DL; Song KW; Power MM; Nitta JY; Dai Y; Smith CA
Biol Blood Marrow Transplant; 2009 Feb; 15(2):205-13. PubMed ID: 19167680
[TBL] [Abstract][Full Text] [Related]
16. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology.
Alessandrino EP; Amadori S; Barosi G; Cazzola M; Grossi A; Liberato LN; Locatelli F; Marchetti M; Morra E; Rebulla P; Visani G; Tura S;
Haematologica; 2002 Dec; 87(12):1286-306. PubMed ID: 12495903
[TBL] [Abstract][Full Text] [Related]
17. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
Schmid C; Schleuning M; Ledderose G; Tischer J; Kolb HJ
J Clin Oncol; 2005 Aug; 23(24):5675-87. PubMed ID: 16110027
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia.
Tauro S; Craddock C; Peggs K; Begum G; Mahendra P; Cook G; Marsh J; Milligan D; Goldstone A; Hunter A; Khwaja A; Chopra R; Littlewood T; Peniket A; Parker A; Jackson G; Hale G; Cook M; Russell N; Mackinnon S
J Clin Oncol; 2005 Dec; 23(36):9387-93. PubMed ID: 16314618
[TBL] [Abstract][Full Text] [Related]
19. The role of stem cell source in autologous hematopoietic stem cell transplantation for patients with myelodysplastic syndromes.
de Witte T; Brand R; van Biezen A; Delforge M; Biersack H; Or R; Meloni G; Bandini B; Sierra J; Kroger N; Gratwohl A; Niederwieser D;
Haematologica; 2006 Jun; 91(6):750-6. PubMed ID: 16769576
[TBL] [Abstract][Full Text] [Related]
20. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
Nakamura R; Rodriguez R; Palmer J; Stein A; Naing A; Tsai N; Chang K; Slovak ML; Bhatia R; Spielberger R; Kogut N; Pullarkat V; Kirschbaum M; Forman SJ; O'Donnell MR
Bone Marrow Transplant; 2007 Nov; 40(9):843-50. PubMed ID: 17724447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
